Merus N.V. (MRUS) PT Raised to $33 at RBC Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Merus N.V. (MRUS) Prices 3.86M Share Offering at $28.50/sh
November 5, 2021 5:39 AM EDTMerus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics), today announced the pricing of an underwritten public offering of 3,859,650 common shares, at a public offering price of $28.50 per share (the Offer Shares). Merus also granted the underwriters a 30-day option to purchase up to an additional 578,947 common shares (the Option Shares and together with the Offer Shares, the Shares). The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses and excluding the underwriters option to purchase the Option Shares, are approximately $110.0 million.... More
Merus N.V. (MRUS) Announces Proposed Stock Offering, Size not Disclosed
November 4, 2021 4:09 PM EDTMerus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the launch of a proposed underwritten public offering of its common shares (the Offer Shares). All of the common shares are being offered by Merus. In addition, Merus expects to grant the underwriters a 30-day option to purchase an additional 15% of the Offer Shares (the Option Shares and together with the Offer Shares, the Shares). The offering is subject to market conditions and other closing conditions, and there can be no assurance as to whether or... More
